-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
TScan Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2020 to Q2 2025.
- TScan Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2025 was -$37M, a 16.7% decline year-over-year.
- TScan Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2025 was -$137M, a 31% decline year-over-year.
- TScan Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$127M, a 42.9% decline from 2023.
- TScan Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$89.2M, a 34.7% decline from 2022.
- TScan Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$66.2M, a 36.2% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)